As biosimilars for innovator biologics advance, drug makers are seeking new indications for products in their portfolios as a means to protect their sales against oncoming—or existing—competition. This month saw 3 notable label developments for drugs made by Janssen, Alexion, and AbbVie.
As biosimilars for innovator biologics advance, drug makers are seeking new indications for products in their portfolios as a means to protect their sales against oncoming—or existing—competition. This month saw 3 notable label developments for drugs made by Janssen, Alexion, and AbbVie.
FDA grants a UC indication for ustekinumab
This week, Janssen announced that the FDA had granted approval for ustekinumab (Stelara) for the treatment of ulcerative colitis (UC).
Approval of the new indication was based on a phase 3 clinical study in which patients with UC received a single intravenous dose of ustekinumab, followed by a maintenance period in which they received subcutaneous ustekinumab treatment every 8 weeks for 44 weeks. In the induction phase, 19% of patients achieved remission by week 8, and in the maintenance period, 45% of patients were in remission—and 43% were in steroid-free remission—at 1 year.
The new indication for the interleukein-12 and -23 antagonist adds to a label that already contains the treatment of plaque psoriasis, psoriatic arthritis, and Crohn disease. The drug was also granted an indication for UC in the European Union in September.
Approval of the new indication comes shortly after biosimilar developer NeuClone announced that it has begun a phase 1 trial of its proposed ustekinumab biosimilar in Australia.
Alexion adds aHUS to ravulizumab’s label
The FDA gave rare disease drug maker Alexion a boost with approval of a new indication for its ravulizumab (Ultomiris), a success for to eculizumab (Soliris) that requires less frequent dosing. The drug is now approved to treat atypical hemolytic uremic syndrome (aHUS), a rare, progressive disease that can lead to irreversible organ damage and premature death.
Ravulizumab, which is administered every 8 weeks versus every 2 weeks for eculizumab, has already gained approval for the treatment of paroxysmal nocturnal hemoglobinuria (PNH), and Alexion is studying the drug in patients with myasthenia gravis.
Alexion said earlier this year that it plans to “convert” its growing base of eculizumab users to ravulizumab as biosimilars of eculizumab approach.
Successor to Humira gets positive CHMP opinion
Finally, AbbVie’s successor to its brand-name adalimumab, Humira, the small-molecule Janus kinase inhibitor upadacitinib (Rinvoq), received a positive opinion from the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) for an indication in rheumatoid arthritis (RA).
The drug maker is now awaiting a final decision from the European Commission, after which, the drug—which is also approved in the United States to treat RA—could help AbbVie to compete in a European RA landscape that now has multiple adalimumab biosimilars available.
While many health systems have reported substantial savings from switching patients to biosimilar adalimumab, upadacitinib could provide some advantages over the older adalimumab; in the SELECT-COMPARE study, upadacitinib outperformed both placebo and adalimumab in terms of the proportion of patients who achieved the American College of Rheumatology (ACR)’s criteria for 20% improvement at week 12 of treatment. The small-molecule drug was also superior to adalimumab in terms of the proportion of patients who reached ACR's criteria for 50% improvement at week 12, as well as in reduction of pain and improvement in quality of life as measured by the Health Assessment Questionnaire Disability Index.
Eye on Pharma: Bevacizumab Update; Samsung Bioepis, J&J Settlement; Another EU Trastuzumab
December 6th 2023Outlook Therapeutics provides an update on the development of its bevacizumab candidate for age-related macular degeneration; Samsung Bioepis settles with Johnson & Johnson (J&J) over its ustekinumab biosimilar candidate; and the European Union gains another trastuzumab biosimilar.
Biosimilar Business Roundup for October 2023—Podcast Edition
November 5th 2023On this episode, we discuss the biggest news to come out of October 2023, including 3 regulatory approvals, 2 complete response letters, and new data and industry insights that have the potential to impact the entire US biosimilar industry.
HHS Praises Biosimilars Savings but Opportunities to Reduce Part B Spending Remain
November 28th 2023Although biosimilars have already generated savings for Medicare Part B programs and beneficiaries, opportunities for substantial reductions in spending remain, according to a report from the HHS.
Biosimilars Regulatory Roundup for September 2023—Podcast Edition
October 1st 2023On this episode, we discuss several regulatory updates from around the globe, including some European and Japanese approvals, the FDA’s 2-day workshop on the present science behind clinical efficacy testing for biosimilars, and streamlining biosimilar development.
Eye on Pharma: Adalimumab Updates; New Eylea Biosimilar Lawsuit; Canada Gains Stelara Biosimilar
November 22nd 2023Several companies make moves to further their adalimumab biosimilars, Regeneron sues Celltrion over biosimilar for Eylea (aflibercept), and Health Canada grants marketing authorization for biosimilar referencing Stelara (ustekinumab).